Endothelin  (ET-) is vasoactive peptide that acts via ET-A receptors coupling inducing vascular smooth muscle cell proliferation and contraction. ET- is involved in the development and maintenance of hypertension. Aim of this study was to determine the contribution of Ras farnesyl transferase, mitogen activated protein kinase (MAP kinase) and cytochrome P¬ (CYP) metabolites to ET- induced hypertension. ET- ( pmol/kg per minute) was chronically infused into to the jugular vein by use of mini-osmotic pump for  days in male Sprague-Dawley rats. Mean arterial blood pressure (MABP) in ET--treated rats was ± mm Hg (hypertensive rats) compared with ± mm Hg in control (normotensive) rats. Infusion of Ras farnesyl transferase inhibitor FPTIII ( ng/min), MAP kinase inhibitor PD- ( ng/min) and CYP inhibitor -ODYA ( ng/min) signifi cantly attenuated MABP to ±. mm Hg, ± mm Hg and ±. mm Hg, respectively. Th ese results suggest that CYP- metabolites and Ras/MAP kinase pathway contribute to the development of ET- induced hypertension. Further investigation has to be done to confi rm whether activation of RAS/MAP kinase pathway by arachidonic acid metabolites plays an important role in the development of ET- induced hypertension. 
INTRODUCTION
There are three mature endothelin isoforms: ET-, ET- and ET-, of which the most potent isoform is endothelin- implicated in the physiological control of vascular smooth muscle cell (VSMC) and myocardial contractility [] . ET- acts via ET-A receptors coupling inducing vascular smooth muscle cell contraction [] . Endothelin-, a -amino acid peptide, is synthesized by the endothelium and it can induce proliferation of vascular smooth muscle cell and thus be implicated in pathogenesis of hypertension [-] . ET- induces arachidonic acid release via activation of cytosolic phospholipase A (cPLA) [] . Arachidonic acid is metabolized by cyclooxygenase into prostaglandins, by lipoxygenase into leukotrienes and by cytochrome P- into -, -, and -HETE [, ] . It has been reported that Ras GTPase/MAP kinase pathway and cytochrome P- metabolites contribute to DOCA-Salt-induced hypertension and angiotension II-induced hypertension, as well [,] . Aim of this study was to determine the contribution of Ras farnesyl transferase, mitogen activated protein kinase (MAP kinase) and cytochrome P¬ (CYP) metabolites to ET- induced hypertension. Since it has been reported that activation of Ras/MAP kinase pathway in angiotensin II-and norepinephrine-induced hypertension is mediated by arachidonic acid metabolites [, , ] , we wanted to analyze whether is the same or similar mechanism in ET- induced hypertension.
MATERIALS AND METHODS

Animals
All studies were done in  to  g male Sprague-Dawley rats purchased from Harlan Sprague-Dawley Inc. Animals were housed in a temperature controlled room ( o C) with a :-hour light/dark cycle. All experiment procedures in this study were done in accordance with National Institutes of Health Guidelines for this kind of study. Animals were divided into: ) control group, ) ET- treated group ( pmol 
Statistical analysis
Values are expressed as mean ± SEM. The data were analyzed by -way ANOVA, and difference between the means for multiple comparisons was determined by the Newman-Keuls test and a value difference of p<. was considered statistically significant. 
RESULTS
Chronic infusion of ET
DISCUSSION
It has been previously reported that Ras/MAP kinase pathway activation by CYP- metabolites contributes to the development of DOCA-Salt-induced hypertension [] . Th e present study demonstrates that Ras/MAP kinase pathway activated probably by CYP- metabolites contributes to the development of ET- induced hypertension, as well.
Other vasoactive agents such as Norepinephrine (NE) and angiotensin II (ANG II) increase CaM kinase II and cPLA activities and thus release arachidonic acid [] . The metabolites of arachidonic acid, such as -and -HETE made via cytocrome P- and lipoxygenase, through Ras/ MEK/MAPK pathway activation contribute to vascular smooth muscle cell proliferation induced by NE or ANG II [, , ] . ET- promotes vascular smooth muscle cell proliferation through extracellular signal-regulated kinase activation mediated by cPLA [] . ET- is involved in the development and maintenance of hypertension [, ] . In our study, administration of ET- produced signifi cant rise in MABP compared with that in control (normotensive) rats. Infusion of Ras farnesyl transferase inhibitor FPTIII, MAP kinase inhibitor PD- and CYP inhibitor -ODYA, but not COX inhibitor indometacin or LO inhibitor baicalein, significantly attenuated MABP. Our findings suggest that ET- induced hypertension is mediated by CYP- metabolites and Ras/MAP kinase pathway activation. Similar results have been reported in DOCA-Salt-, norepinephrineand Angiotensin II-induced hypertension, as well [,,] .
CONCLUSION
Th e present study demonstrates that Ras/MAP kinase pathway activated probably by CYP- metabolites contributes to the development of ET- induced hypertension. It seems to be common mechanism by which ET-, ANG II and NE induce hypertension. Further investigation has to be done to confirm whether activation of RAS/MAP kinase signal transduction pathway induced by different vasoactive agents by arachidonic acid metabolites is a universal mechanism in the development of hypertension.
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